EXACT Sciences Co. (NASDAQ:EXAS) insider Kevin T. Conroy sold 25,319 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $42.34, for a total transaction of $1,072,006.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of EXACT Sciences Co. (EXAS) traded up $1.81 on Tuesday, hitting $44.37. 4,378,424 shares of the stock were exchanged, compared to its average volume of 3,460,000. EXACT Sciences Co. has a fifty-two week low of $19.91 and a fifty-two week high of $63.60. The firm has a market cap of $5,310.00, a price-to-earnings ratio of -21.75 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.15 and a quick ratio of 6.77.
EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Thursday, February 22nd. The medical research company reported ($0.18) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.09. EXACT Sciences had a negative net margin of 43.01% and a negative return on equity of 24.13%. The business had revenue of $87.41 million for the quarter, compared to analyst estimates of $87.42 million. During the same period last year, the business earned ($0.34) EPS. The company’s revenue was up 148.0% on a year-over-year basis. equities research analysts expect that EXACT Sciences Co. will post -0.69 EPS for the current year.
EXAS has been the subject of several recent research reports. BidaskClub cut shares of EXACT Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. Bank of America raised their price target on shares of EXACT Sciences from $58.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, November 29th. Canaccord Genuity raised shares of EXACT Sciences to a “buy” rating and set a $60.00 price target for the company in a research report on Tuesday, October 31st. Craig Hallum raised their price target on shares of EXACT Sciences from $46.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, October 31st. Finally, Benchmark reissued a “buy” rating and issued a $60.00 price target (up previously from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $52.84.
COPYRIGHT VIOLATION WARNING: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3226609/kevin-t-conroy-sells-25319-shares-of-exact-sciences-co-exas-stock.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.